Education
About Us
Working with TipRanks
Follow Us
Kane Biotech Inc (TSE:KNE)
:KNE
Total Valuation
Kane Biotech has a market cap or net worth of C$13.06M. The enterprise value is C$20.47M.
Market CapC$13.06M
Enterprise ValueC$20.47M
Share Statistics
Kane Biotech has 137,511,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding137,511,570
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kane Biotech’s return on equity (ROE) is 0.48 and return on invested capital (ROIC) is -179.47%.
Return on Equity (ROE)0.48
Return on Assets (ROA)-0.89
Return on Invested Capital (ROIC)-179.47%
Return on Capital Employed (ROCE)0.64
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.03
Inventory Turnover0.16
Valuation Ratios
The current PE Ratio of Kane Biotech is -2.23. Kane Biotech’s PEG ratio is -0.19.
PE Ratio-2.23
PS Ratio308.73
PB Ratio-1.06
Price to Fair Value-1.06
Price to FCF-3.47
Price to Operating Cash Flow-3.48
PEG Ratio-0.19
Income Statement
In the last 12 months, Kane Biotech had revenue of 148.98K and earned -5.03M in profits. Earnings per share was -0.04.
Revenue148.98K
Gross Profit109.47K
Operating Income-3.36M
Pretax Income-4.56M
Net Income-5.03M
EBITDA-3.23M
Earnings Per Share (EPS)-0.04
Cash Flow
In the last 12 months, operating cash flow was -5.62M and capital expenditures -49.29K, giving a free cash flow of -5.67M billion.
Operating Cash Flow-5.62M
Free Cash Flow-5.67M
Free Cash Flow per Share-0.04
Dividends & Yields
Kane Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.47
52-Week Price Change-25.00%
50-Day Moving Average0.10
200-Day Moving Average0.12
Relative Strength Index (RSI)44.02
Average Volume (3m)27.59K
Important Dates
Kane Biotech upcoming earnings date is May 22, 2025, TBA Not Confirmed.
Last Earnings DateApr 1, 2025
Next Earnings DateMay 22, 2025
Ex-Dividend Date―
Financial Position
Kane Biotech as a current ratio of 0.34, with Debt / Equity ratio of -331.42%
Current Ratio0.34
Quick Ratio0.32
Debt to Market Cap0.74
Net Debt to EBITDA-2.63
Interest Coverage Ratio-2.76
Taxes
In the past 12 months, Kane Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kane Biotech EV to EBITDA ratio is -6.10, with an EV/FCF ratio of -6.11.
EV to Sales132.44
EV to EBITDA-6.10
EV to Free Cash Flow-6.11
EV to Operating Cash Flow-6.12
Balance Sheet
Kane Biotech has C$544.38K in cash and marketable securities with C$0.00 in debt, giving a net cash position of C$1.74M billion.
Cash & Marketable SecuritiesC$544.38K
Total DebtC$0.00
Net CashC$1.74M
Net Cash Per ShareC$0.01
Tangible Book Value Per Share-C$0.07
Margins
Gross margin is -7.83%, with operating margin of -2253.58%, and net profit margin of -3379.05%.
Gross Margin-7.83%
Operating Margin-2253.58%
Pretax Margin-3062.39%
Net Profit Margin-3379.05%
EBITDA Margin-2171.04%
EBIT Margin-2246.83%
Analyst Forecast
The average price target for Kane Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―